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Abstract
Background: Pregnancy-associated plasma protein A (PAPP-A) is abundantly expressed in carotid plaques. This
study investigated the association between single nucleotide polymorphisms (SNPs) of PAPP-A and the presence of
carotid plaques.
Methods: A total of 408 patients with carotid plaques and 493 controls were included in the study. All subjects
were Southern Chinese Han. Carotid plaques were analyzed by computer tomography angiography. PAPP-A SNPs
were identified by ligase detection reaction-polymerase chain reaction analysis. The PAPP-A genotypes rs3747823,
rs7020782, and rs13290387 were analyzed.
Results: The rs7020782 C allele genotype correlated with an increased risk of developing carotid plaques under the
dominant, recessive, and additive models (adjusted odds ratios: 2.60, 2.36, and 3.48, respectively; P ≤ 0.001). Only C
allele-carrying genotypes correlated with a significantly increased risk of carotid plaque based on studies stratified
by age and sex under the dominant model. rs7020782 remained significantly associated with the risk of carotid
plaque calcification after adjusting for age and potential confounders (adjusted odds ratio, 1.89; 95 % confidence
interval, 1.17–3.08; P = 0.010).
Conclusions: This study found, for the first time, that the A˃C variation of rs7020782 might be an independent risk
factor for carotid plaque development and calcification. The determination of such genotypes could provide a new
tool for identifying individuals at high risk for carotid atherosclerosis.
Keywords: Calcified plaque, Carotid plaque, Pregnancy-associated plasma protein A, Single nucleotide
polymorphisms
Background
Pregnancy-associated plasma protein A (PAPP-A) is a
metalloproteinase that regulates insulin-like growth fac-
tor (IGF) and acts as a biomarker of inflammation [1–4].
It is abundantly expressed in carotid plaques, which
form an important pathological basis of strokes. A num-
ber of studies have reported that its increased levels
might be recognized as a promising biomarker for acute
coronary syndromes [5–7], cerebrovascular events [8, 9],
and systemic atherosclerotic disease [10]. It has also
been suggested that PAPP-A concentrations could be a
marker for carotid atherosclerosis [11] as well as carotid
plaque destabilization and rupture [12, 13].
Although PAPP-A appears to be a key factor in the
progressive advanced stage of atherosclerosis [14], its
precise role outside pregnancy is yet to be clarified [15].
PAPP-A expression has been linked with carotid vulner-
able plaque development, and serum PAPP-A levels with
carotid atherosclerosis. Therefore, the association be-
tween PAPP-A and carotid plaques deserves further re-
search [13, 16].
A previous study revealed an association between
PAPP-A polymorphisms and acute myocardial infarction
[17]. Additionally, in 2012, Wang et al. reported that
genetic polymorphisms of PPAP-A were correlated with
ischemic stroke [18]. More recently, another study
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investigated the relationship between serum PAPP-A
levels and coronary plaque characteristics [19]. However,
little is known about the association between PAPP-A
polymorphisms and carotid plaques.
China has a growing population that is increasingly
aging, and has seen a rapid rise in the incidence of cere-
brovascular events. The prevention and treatment of
these is therefore an important public health problem.
The identification of patients at high risk of developing
carotid plaques may help the prevention of cerebrovas-
cular events. Therefore, in our present study, we selected
three single nucleotide polymorphisms (SNPs) of PAPP-
A (rs3747823, rs7020782 and rs13290387) according to
literature [18, 17] may be related to vascular diseases to
investigate the association of PAPP-A polymorphisms
with carotid plaque development.
Methods
Subjects
The study included a total of 901 subjects aged 50 years
and above; 408 subjects had carotid plaques and 493
were controls without carotid plaques. Those subjects
diagnosed with carotid atherosclerosis by computed
tomography angiography (CTA) were enrolled at the
Division of Neurology of Daping Hospital (Chongqing,
China) between January 2011 and December 2012. The
controls were selected during the same period from the
same hospital, and were shown not to have carotid ath-
erosclerosis by CTA. All subjects were Southern Chinese
Han. CTA carotid plaque characterization was defined
as follows: (1) cut-off value to differentiate lipid core
from fibrous tissue and fibrous tissue from calcifications:
60 Hounsfield Units (HU) and 130 HU, respectively [20],
based on multi-detector CTA measurements; (2) cut-off
point between calcifications and non-calcified tissue: 130
HU [20]; (3) cut-off point between lumen and athero-
sclerotic vessel wall: 200 HU [20]. Two experienced radi-
ologists and two neurologists who were both blinded to
the genotype read the scans and reached an agreement
about diagnosis. The Ethics Committee of Daping Hos-
pital approved the study and all subjects signed an in-
formed consent form.
Exclusion criteria included patients with: (1) acute cor-
onary syndrome; (2) liver or kidney dysfunctions or se-
vere heart failure; (3) infections or immune system
diseases; (4) peripheral vascular diseases; (5) cerebral in-
farction induced by arteritis, blood diseases, cancer,
drugs, aneurysms, or vascular malformations.
Collection of clinical data and laboratory measurements
Subject body weight and height were measured directly.
Blood pressure was measured with a mercury-column
sphygmomanometer after 10 min of rest in the supine
position. Body mass index (BMI) was calculated using
body weight (kg) divided by squared height (m2). Fasting
plasma glucose (FPG), total plasma cholesterol (TC), tri-
glycerides (TG), low density lipoprotein cholesterol
(LDL-C), and high density lipoprotein cholesterol (HDL-
C) were measured using standard enzymatic techniques.
Blood samples (10 ml) were drawn in the morning
after an overnight fast from the peripheral vein of supine
patients. The blood sample was immediately separated
by centrifugation at 2,000 × g for 15 min at 4 °C. After
centrifugation, the separated plasma samples were fro-
zen at −80 °C until analysis. The leukocytes were col-
lected in Eppendorf tube for genetic analysis. Smoking
was defined as regular cigarette smoking or the use of
any tobacco products on a weekly basis or more often,
or regular smoking in the past [21].
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using a commercial blood DNA extract kit (Axy-
gen AxyPrep ™ Mag Blood Genomic DNA Kits, USA)
and was stored at −20 °C until used for genotype testing.
Genotype data of the Chinese Han sample (CHB sample)
were downloaded from the HapMap database (http://
www.hapmap.org, HapMap Public Release #2), and the
minor allele frequencies of the three SNPs > 0.05. The
genotyping of rs3747823, rs7020782 and rs13290387 was
carried out by the Shanghai BioWing Applied Biotechnol-
ogy Company (http://www.biowing.com.cn/) using ligase
detection reaction-polymerase chain reaction (LDR-PCR)
[22–26]. The primer and probe sequences and PCR and
LDR product lengths of the variant are summarized in
Additional file 1: Table S1. Fragment amplification was
carried out in 20 μl of multiplex PCR mixture containing
50 ng (1 μl) of genomic DNA, 2 μl of 1 × buffer, 0.6 μl of
Mg 2+(3 mM), 2 μl of dNTPs (2 mM), 0.3 μl of Taq poly-
merase (1U), 4 μl of 1 ×Q-solution, 0.4 μl of primer mix
and 9.7 μl of ddH2O. The PCR included initial denaturing
at 95 °C for 15 min, followed by 35 cycles of denaturing at
94 °C for 30 s, annealing at 56 °C for 30 s, and extension
at 72 °C for 1 min. The reaction was completed by a final
extension at 72 °C for 10 min. Reactions were performed
on a thermal cycler Gene Amp PCR system 9600 (Perkin
Elmer, Waltham, MA, USA). Further amplification was
performed in a 10 μl volume of multiplex LDR reaction
mixture, containing 1 μl (100 ng) of the resultant probe
mix, 1 μl of probe mix (12.5pmol/μl), 0.05 μl NEB Taq
DNA ligase (2U) and 7.95 μl of ddH2O. The LDR condi-
tions included initial denaturing at 95 °C for 2 min,
followed by 30 cycles of denaturing at 94 °C for 15 s and
annealing at 50 °C for 25 s. LDR products (1 μl) were
mixed with 1 μl of ROX (ABI, Foster City, CA, USA) and
1 μl of loading buffer, detected in an ABI PRISM 377
DNA Sequencer, and analyzed with Gene-mapper (ABI,
Foster City, CA, USA).
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Statistical analysis
Statistical analysis was performed using the PASW sta-
tistics 18 (International Business Machines Corp., New
York, USA). Categorical variables were compared using
the chi-squared test (χ2), and continuous variables com-
pared using the Student’s t-test. Hardy–Weinberg equi-
librium (HWE) was assessed by the χ2-test. Distributions
of genotypes between cases and controls were also ana-
lyzed by the χ2-test. To assess the association of PAPP-A
SNPs with carotid plaques, univariate and multivariate
logistic regression analysis were used to calculate crude
and adjusted odds ratios (ORs) with 95 % confidence in-
tervals (95 % CI). Confounding risk factors such as age,
sex, BMI, smoking, blood pressure, FPG, TC, TG, LDL-
C, and HDL-C were assessed for significance using the
logistic regression model. A two-tailed test of P < 0.05
was considered statistically significant.
Results
The clinical characteristics of the subjects are shown in
Table 1. Compared with controls, subjects with carotid
plaques were significantly older, with a significantly
higher incidence of males, and significantly higher sys-
tolic blood pressure, higher diastolic blood pressure, and
lower HDL-C levels (P < 0.05). There were no significant
differences in FPG, TC, TG, LDL-C, BMI, or smoking
between the two groups.
PAPP-A SNP genotypes in carotid plaque and control
groups are shown in Table 2. The genotype distributions
of all SNPs were compatible with HWE in both the ca-
rotid plaque and control groups (P > 0.05, omitted).
There was no significant difference in the distributions
of rs3747823 or rs13290387 genotypes between the ca-
rotid plaque and control groups under the three
models. However, there was a significant difference in
the distribution of the rs7020782 genotype under all
three models between the carotid plaque and control
groups (P < 0.001).
As shown in Table 3, logistic regression analysis re-
vealed that the rs7020782 genotype was associated with
an increased risk of carotid plaques in dominant, reces-
sive, and additive models. After adjusting for age, gender,
systolic and diastolic blood pressure, and HDL-C, a sig-
nificant correlation still remained (adjusted OR, 2.60,
2.36, 3.48, respectively; 95 % CI, 1.93–3.48, 1.42–3.92,
2.05–5.92, respectively; P < 0.001).
The significant association of PAPP-A SNPs with
plaque characteristics in the patient group is shown in
Fig. 1. The rs7020782 genotype correlated with calcified
and non-calcified plaque under the C allele dominant
model. The χ2-test revealed that the C allele dominant
model of rs7020782 was associated with an increased
risk of carotid calcified plaque (OR, 1.86; 95 % CI, 1.16–
2.98; P = 0.010). After adjusting for age and other poten-
tial confounders by multivariate logistic regression
analysis, a significant correlation of rs7020782 with an
increased risk of carotid calcified plaque still remained
(OR, 1.89; 95 % CI, 1.17–3.08, P = 0.010). This indicates
that the rs7020782 genotype is associated with a risk of
calcified plaque in the C allele dominant model. C allele
variations showed no association with plaque calcifica-
tion in recessive or additive models. Moreover, the other
two SNPs did not appear to be associated with carotid
plaque calcification under all three models.
We also observed a remarkable mutual effect between
C allele-carrying genotypes and an increased risk of ca-
rotid plaque based on stratified analyses by sex and age
under the dominant model (Figs. 2 and 3). After adjust-
ing the variables of confounding factors, an elevated risk
of carotid plaque correlated with the C allele dominant
model was evident in female subjects (OR, 2.08; 95 % CI,
1.38–3.14; P < 0.001), male subjects (OR, 3.14; 95 % CI,
Table 1 Clinic characteristics of subjects with carotid plaque and controls
Characteristics Carotid plaque (n = 408) Controls (n = 493) P value
Age (years) 68.29 ± 9.80 64.89 ± 9.16 <0.001
Female (%) 44.36 57.4 <0.001
BMI (Kg/m2) 23.66 ± 3.98 23.60 ± 3.21 NS
Systolic blood pressure (mmHg) 136.35 ± 16.18 127.75 ± 16.48 <0.001
Diastolic blood pressure (mmHg) 81.49 ± 10.21 76.02 ± 9.47 <0.001
Fasting plasma glucose (mmol/L) 5.53 ± 1.81 5.60 ± 1.68 NS
Smoking (%) 33.58 30.43 NS
TC (mmol/L) 4.75 ± 1.05 4.85 ± 1.11 NS
TG (mmol/L) 1.54 ± 1.11 1.50 ± 1.11 NS
LDL-C (mmol/L) 2.58 ± 0.74 2.59 ± 0.75 NS
HDL-C (mmol/L) 1.14 ± 0.31 1.22 ± 0.33 <0.001
Value expressed by mean ± SD
BMI, body mass index; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; NS,
no significance
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2.05–4.81; P < 0.001), subjects aged ≤64 years (OR, 2.33;
95 % CI, 1.47–3.69; P < 0.001), and those aged > 64 years
(OR, 2.57; 95 % CI, 1.75–3.76; P < 0.001). Under the reces-
sive model, no significant correlation was found in female
subjects or those aged ≤64 years. Under the additive
model, no significant correlation was found in subjects
aged ≤64 years. These results indicate that only the C al-
lele dominant model variant was significantly associated
with carotid plaque development in each stratified study.
Discussion
The present study investigated whether PAPP-A poly-
morphisms contributed to susceptibility to carotid pla-
ques in a Southern Chinese Han population containing
408 patients and 493 controls. Our results showed that
the SNP rs7020782 was significantly associated with an
increased risk of carotid plaques, but no association was
found for rs3747823 or rs13290387.
PAPP-A belongs to the metzincin superfamily of me-
talloproteinases [2] and is the founding member of a
new metzincin subfamily, which differs from the four
existing subfamilies (matrix metalloproteases, astacins,
adamalysins/reprolysins, and serralysins) [15]. Djurić et al.
[27] found that the MMP-1 − 1062 G/2G polymorphism
and specific haplotypes of three other promoter polymor-
phisms were significantly and independently associated
with the occurrence of carotid plaques, while Li et al. [28]
reported that the inter-individual variability in MMP-12
variation may not be a risk factor for carotid plaques in
the Chinese Han population.
Dong et al. [29] conducted a follow-up association
study of linkage regions, which identified multiple can-
didate genes for carotid plaque development in a
population from the Dominican Republic. In a family
study, evidence for association was found regarding
several genes (NAV2, EFCAB11/TDP1, AGBL1, PTPN9,
LINGO1, and LOC730118), with the strongest association
at rs4143999 near EFCAB11/TDP1. Osteoprotegerin gene
(TNFRSF11B) polymorphisms were also recently shown
to be potential markers for carotid calcified plaques in pa-
tients with carotid atherosclerosis [30]. The observed cor-
onary artery calcification was associated with the human
Table 2 Association study of four SNPs in PAPP-A under different models in two groups
Carotid plaque Controls
Analyzing Model: SNPs n1 Frequency (%) n1 Frequency (%) P value §
rs3747823
Additive: GG/AG/AA 263/126/18 64.6/31.0/4.4 298/155/27 62.1/32.3/5.6 NS
Dominant: (AA + AG)/GG 144/263 35.4/64.6 182/298 38.0/62.0 NS
Recessive: AA/(AG + GG) 18/389 4.4/95.6 27/453 5.6/94.4 NS
rs7020782
Additive: AA/AC/CC 166/190/51 40.8/46.7/12.5 302/159/29 61.6/32.4/6.0 <0.001
Dominant: (AC + CC)/AA 241/166 59.2/40.8 188/302 38.4/61.6 <0.001
recessive: CC/(AC + AA) 51/356 12.5/87.5 29/461 5.9/94.1 0.001
rs13290387
Additive: GG/CG/CC 207/163/31 51.6/40.6/7.7 269/179/35 55.7/37.1/7.2 NS
Dominant: (CG + CC)/GG 194/207 48.4/51.6 214/269 44.3/55.7 NS
Recessive: CC/(CG + GG) 31/370 7.7/92.3 35/448 7.2/92.8 NS
§P-values were calculated by Pearson Chi-Squared test. NS, no significance
1The number did not add up to 408 or 493, because the SNPs genotyping with LDR method had the absent value inevitably
Table 3 Risk of carotid plaque under different models of PAPP-A SNPs
SNPs analyzing Model‡ Crude OR (95 % CI) 1 P value1 Adjusted OR (95 % CI)§ P value§
rs7020782
Dominant 2.33 (1.79-3.05) <0.001 2.60 (1.93-3.48) <0.001
Recessive 2.28 (1.41-3.66) 0.001 2.36 (1.42-3.92) 0.001
Additive 3.20 (1.95-5.24)† <0.001 3.48 (2.05-5.92)† <0.001
1 Un-adjusted logistic regression model; OR, odds ratio
§Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, high density lipoprotein cholesterol
‡In analyses, a additive effect of the variant (V) allele was assumed, the genotype wild (W) W/W,W/V and V/V were coded as 1,2, and 3, respectively; when a
dominant effect was assumed, genotype W/W was coded as 2, and an W/V and V/V combined were coded as 1. Accordingly, scores of 2 for W/W, W/V combined
and of 1 for V/V were used in the assumed recessive effect
†Referred to AC vs. AA; CC vs. AA was not significant in additive model in logistic regression
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chromosome 9p21 locus SNPs [31], which prompted the
research of genetic variants with vascular calcification and
the underlying mechanism of vascular diseases [32–35].
PAPP-A has previously been investigated as a candi-
date gene for cerebrovascular diseases. A retrospective
study also showed that C allele-carrying genotypes of
rs7020782 have a higher risk of developing ischemic
stroke compared to the GG genotype among a Northern
Chinese Han population [18]. Thus far, however, few
studies have explored the relationship between PAPP-A
variants and carotid plaques, although the present study
identified an association with SNP rs7020782. This SNP
is in exon 14 of PAPP-A, and was previously reported to
be associated with recurrent pregnancy loss [36]. The
A > C allele variant (Tyr/Ser) of rs7020782 may influence
PAPP-A protein determination in risk assessment screen-
ing during the first trimester of pregnancy [37].
Although the development of carotid plaques appears
to be associated with PAPP-A SNP rs7020782, the pre-
cise molecular mechanism behind this development re-
mains unclear [38]. Our study was limited by including
only a relatively small number of subjects and investigat-
ing only three SNPs, so future studies of larger sample
sizes and more PAPP-A SNPs should be carried out. The
association between PAPP-A levels and PAPP-A poly-
morphisms rs7020782 should therefore be evaluated in
future work to illuminate whether this SNP in exon 14
of PAPP-A influences serum PAPP-A concentrations.
Fig. 1 Dominant model of rs7020782 C allele in subjects with calcified plaque and non-calcified plaque. Chi-Squared test for categorical values
Pearson χ2 = 6.665, P = 0.010 for genotype frequency. CP: calcified plaque NCP: non-calcified plaque. Adjusted for age, sex, systolic blood pressure,
diastolic blood pressure, high density lipoprotein cholesterol, the risk of calcified plaque: odds ratio, 1.89, 95 % CI,1.17-3.08, P = 0.010
Fig. 2 Stratified distribution of rs7020782 genotypes by sex in subjects
with carotid plaque and controls. Adjusted for age, systolic blood
pressure, diastolic blood pressure, high density lipoprotein cholesterol,
the risk of carotid plaque under C allele dominant model in female
subjects*: odds ratio, 2.08; 95 % CI, 1.38–3.14; P < 0.001, male subjects**
: odds ratio, 3.14; 95 % CI, 2.05–4.81; P < 0.001
Fig. 3 Stratified distribution of rs7020782 genotypes by age in subjects
with carotid plaque and controls. Adjusted for sex, systolic blood
pressure, diastolic blood pressure, high density lipoprotein cholesterol,
the risk of carotid plaque under C allele dominant model in subjects
aged ≤64 years *: odds ratio, 2.33; 95 % CI, 1.47–3.69; P < 0.001, those
aged > 64 years** : odds ratio, 2.57; 95 % CI, 1.75–3.76; P < 0.001
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Conclusions
In summary, to our knowledge this is the first study to
investigate the association of PAPP-A SNPs with the risk
of carotid plaque in a Chinese Han population. Our re-
sults indicate that SNP rs7020782 contributes to carotid
plaque susceptibility in this cohort.
Additional file
Additional file 1: Table S1. Primer and probe sequence and PCR and
LDR product length of PAPP-A variants.
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